Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy

Li, Yongshuang; Hou, Hao; Zhang, Peng; Zhang, Zhe

doi:10.1080/10717544.2020.1785049

Cited by 55 publications

(25 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chemotherapy has become the patients’ choice for OSA treatment; however, systematic chemotherapeutics induce considerable cardiac and nephron-toxicity [ 18 ]. Thus, the use of conventional chemotherapeutics for treating OSA patients is limited by their unfavorable side effects [ 19 ]. In addition, poor response to chemotherapeutic regimens might occur, due to the heterogeneity and the genomic complexity of OSA [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma

et al. 2021

View full text Add to dashboard Cite

Osteosarcoma (OSA) is a type of bone cancer that begins in the cells that form bones. OSA is a rare mesenchymal bone neoplasm derived from mesenchymal stem cells. Genome disorganization, chromosomal modifications, deregulation of tumor suppressor genes, and DNA repair defects are the factors most responsible for OSA development. Despite significant advances in the diagnosing and treatment of OSA, patients’ overall survival has not improved within the last twenty years. Lately, advances in modern nanotechnology have spurred development in OSA management and offered several advantages to overcome the drawbacks of conventional therapies. This technology has allowed the practical design of nanoscale devices combined with numerous functional molecules, including tumor-specific ligands, antibodies, anti-cancer drugs, and imaging probes. Thanks to their small sizes, desirable drug encapsulation efficiency, and good bioavailability, functionalized nanomaterials have found wide-spread applications for combating OSA progression. This review invokes the possible utility of engineered nanomaterials in OSA diagnosis and treatment, motivating the researchers to seek new strategies for tackling the challenges associated with it.

show abstract

Section: Introductionmentioning

confidence: 99%

Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, clinical limitations of MET still exist because of its short half-life and weak bioavailability, and high doses of this drug cause unexpected side effects (e.g. lactic acidosis and liver dysfunction) (Li et al., 2019 , 2020 ; Cheng et al., 2019 ). In addition, the differences in the drug administration routines followed for hydrophobic DOX and hydrophilic MET result in differences in their pharmacodynamics, causing time discrepancies in drug metabolism, and decrease the effective co-accumulation of the two drugs in tumor targeting (Da Silva et al., 2019 ; Wang et al., 2020c ; Sun et al., 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Self-assembled polymeric nanocarrier-mediated co-delivery of metformin and doxorubicin for melanoma therapy

et al. 2021

View full text Add to dashboard Cite

Malignant melanoma is a life-threatening form of skin cancer with a low response rate to single-agent chemotherapy. Although combined therapies of metformin (MET) and doxorubicin (DOX) are effective in treating a variety of cancers, including breast cancer, their different physicochemical properties and administration routines reduce the effective co-accumulation of both drugs in tumors. Nanoparticles (NPs) have been demonstrated to potentially improve drug delivery efficiency in cancer therapy of, for example, liver and lung cancers. Hence, in this study, we prepared pH-sensitive, biocompatible, tumor-targeting NPs based on the conjugation of biomaterials, including sodium alginate, cholesterol, and folic acid (FCA). As expected, since cholesterol and folic acid are two essentials, but insufficient, substrates for melanoma growth, we observed that the FCA NPs specifically and highly effectively accumulated in xenograft melanoma tumors. Taking advantage of the FCA NP system, we successfully co-delivered a combination of MET and DOX into melanoma tumors to trigger pyroptosis, apoptosis, and necroptosis (PANoptosis) of the melanoma cells, thus blocking melanoma progression. Combined, the establishment of such an FCA NP system provides a promising vector for effective drug delivery into melanoma and increases the possibility and efficiency of drug combinations for cancer treatment.

show abstract

“… 12 Evidence has shown that the combination of two anticancer drugs in cancer therapies can diminish the adverse effects and suppress the occurrence of drug resistance. 12 …”

Section: Introductionmentioning

confidence: 99%

β-Elemene Enhances the Sensitivity of Osteosarcoma Cells to Doxorubicin via Downregulation of Peroxiredoxin-1

Zhang¹,

Guo²

2021

OTT

View full text Add to dashboard Cite

Background Doxorubicin (Dox) resistance is a primary obstacle for the treatment of osteosarcoma. Meanwhile, β-Elemene was shown to exhibit an anti-proliferative effect on osteosarcoma cells. However, the role of a combination of Dox with β-Elemene on osteosarcoma cells remains unclear. Thus, this study aimed to investigate the role of the combination of Dox with β-Elemene on the proliferation, apoptosis and oxidative stress of Dox-resistance osteosarcoma cells. Methods CKC-8, EdU staining and flow cytometry assays were used to determine the viability, proliferation and apoptosis of Dox-resistance osteosarcoma cells, respectively. Meanwhile, the expression of antioxidant protein peroxiredoxin-1 (Prx-1) in Dox-resistance osteosarcoma cells was detected with Western blot assay. Results In this study, the inhibitory effects of Dox on the viability and proliferation of Dox-resistance osteosarcoma cells were significantly enhanced by β-Elemene. In addition, the combination of Dox and β-Elemene markedly induced the apoptosis and oxidative stress in Dox-resistance osteosarcoma cells. Moreover, combination treatment notably downregulated the expression of Prx-1 in Dox-resistance osteosarcoma cells, indicating that combination treatment inhibited the antioxidant capacity of Dox-resistance osteosarcoma cells. In vivo experiments confirmed that β-Elemene could enhance the anti-tumor effect of Dox in Saos-2/Dox xenograft model. Conclusion We found that β-Elemene could reverse Dox resistance in Dox-resistance osteosarcoma cells via inhibition of Prx-1. Therefore, combining Dox with β-Elemene might be considered as a therapeutic approach for the treatment of Dox-resistant osteosarcoma.

show abstract

Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy

Cited by 55 publications

References 52 publications

Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma

Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma

Self-assembled polymeric nanocarrier-mediated co-delivery of metformin and doxorubicin for melanoma therapy

β-Elemene Enhances the Sensitivity of Osteosarcoma Cells to Doxorubicin via Downregulation of Peroxiredoxin-1

Contact Info

Product

Resources

About